Bank of Nova Scotia »

Halozyme Therapeutics shares owned by Bank of Nova Scotia

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Bank of Nova Scotia from 13F filings

Historical chart of Bank of Nova Scotia investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Bank of Nova Scotia consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Bank of Nova Scotia

Quarter filed Position value Share count Share price at filing
2025-09-30 $5.9M 81k 73.34

More positions owned by Bank of Nova Scotia

NVIDIA Corporation (NVDA)
Apple (AAPL)
Key (KEY)
Rbc Cad (RY)
Microsoft Corporation (MSFT)
Toronto Dominion Bk Ont Com New (TD)
Ishares Tr Core S&p500 Etf (IVV)
Alphabet Cap Stk Cl C (GOOG)
Amazon (AMZN)
Cibc Cad (CM)
Broadcom (AVGO)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Bank Of Montreal Cadcom (BMO)
Brookfield Corp Cl A Ltd Vt Sh (BN)
Meta Platforms Cl A (META)

View all positions for Bank of Nova Scotia

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Arrowstreet Capital, Limited Partnership
Invesco
UBS Group
Snyder Capital Management
D. E. Shaw & Co
Geode Capital Management
Dimensional Fund Advisors
Alliancebernstein
Morgan Stanley
Macquarie Group
Federated Investors
Congress Asset Management

View all funds holding Halozyme Therapeutics